Ever since the first cases of pneumonia of unknown origin were described in Wuhan, China in January 2020, COVID-19 has rapidly spread worldwide resulting in a public health emergency. Fever, myalgia, and respiratory symptoms such as dry cough and dyspnea are common presentations. Complications described in the Intensive Care Unit (ICU) include shock, Acute Respiratory Distress Syndrome (ARDS), arrhythmias and acute cardiac injury.2 Case reports of cardiac involvement including Acute ST-Elevation Myocardial infarction, myocarditis, stress cardiomyopathy and arrhythmias have also been reported.3-5
We describe a case of a patient presenting to the hospital with COVID-19 infection and subsequently developing a pericardial effusion with cardiac tamponade.
While viral infections such as Epstein-Barr virus, Parvovirus B19 and Coxsackievirus are known to cause pericarditis and pericardial effusion, little is known about the pericardial complications of COVID-19 and their pathophysiology. 6 The fibrinoid appearance of pericardial effusion has been strongly associated with pericardial inflammation, as in the case of tuberculoid, bacterial or malignant pericardial effusion.7,8 This could also be postulated to be due to increased viral expression in the heart via angiotensin-converting enzyme 2 (ACE2) as the entry receptor, resulting in an inflammatory response, although more studies are required to substantiate this. 9 We described a case, to our knowledge, the first case of tuberculous pericarditis with tamponade in COVID-19 infection. The appearance of fibrin, lymphocyte rich, elevated adenosine deaminase level with detection of acid fast bacilli and positive TB PCR in the pericardial fluid is pathognomonic of tuberculous involvement. 10,11 There is a possibility that COVID-19 infection induced an inflammatory response that serves as a nidus for TB reactivation in this patient. In addition, this may explain the rapid progression of pericardial tamponade as TB normally runs an indolent course. TB pericarditis is closely linked to constrictive pericarditis with significant morbidity and mortality.1 Treatment with steroids may shorten the time to resolution of symptoms, such as tachycardia and restriction of activity. However, this was not shown to reduce mortality or retard the progression to irreversible constrictive pericarditis.12
To date, there is an increasing number of case reports describing cardiac involvement with COVID-19 infection. Certain cardiac manifestations such as myocarditis and pericardial effusion can be missed without awareness and heightened clinical suspicion. Case series from Italy reported 20 patients with active TB who developed COVID-19 infection subsequently, but none was associated with pericarditis or tamponade. 13
In conclusion, TB pericarditis is a rare manifestation of rapid development of massive pericardial effusion. The presence of TB pericarditis, and consequently its risk, may not be easily identified in the face of COVID-19 pandemic. Thus, a low threshold to use serial echocardiography and dedicated imaging modalities, including CT may be appropriate, particularly in young patient who deteriorate at an alarming speed. Noteworthy, to the best of our knowledge, the current case comprises the first case of concurrent tuberculous pericarditis with tamponade in COVID-19.